Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 17, 2026.

High Cortisol and the Risk of Dementia and Alzheimer’s Disease: A Review of the Literature

Sami Ouanes, Julius Popp

Frontiers in Aging Neuroscience · 2019 · Review · CC BY

doi:10.3389/fnagi.2019.00043

Abstract

Introduction: Cortisol effects on the brain are exerted through two distinct receptors, inducing complex and even opposite effects on the cerebral structures implicated in the various cognitive functions. High cortisol may also have deleterious effects on the brain structures and contribute to neurodegeneration, in particular Alzheimer’s disease (AD), via different mechanisms. Objective: To examine the interrelationships between cortisol, cognitive impairment and AD. Methods: Review of the literature. Results: Clinical studies found that elevated cortisol was associated with poorer overall cognitive functioning, as well as with poorer episodic memory, executive functioning, language, spatial memory, processing speed, and social cognition; while in animals, glucocorticoid administration resulted in cognitive impairment and abnormal behavior. In cognitively healthy subjects, higher cortisol levels have been associated with an increased risk of cognitive decline and AD. Subjects with dementia and Mild Cognitive Impairment (MCI) due to AD have been found to have higher CSF cortisol levels than cognitively healthy controls. Elevated CSF cortisol may also be associated with a more rapid cognitive decline in MCI due to AD. Elevated cortisol levels have been also found in delirium. High cortisol may mediate the impact of stressful life events, high neuroticism, depression, sleep disturbances, as well as cardiovascular risk factors on cognitive performance, neurodegeneration, and cognitive decline. High cortisol may also exert neurotoxic effects on the hippocampus, and promote oxidative stress and amyloid β peptide toxicity. Further possible underlying mechanisms include the interactions of cortisol with inflammatory mediators, neurotransmitters, and growth factors. Conclusions: Elevated cortisol levels may exert detrimental effects on cognition and contribute to AD pathology. Further studies are needed to investigate cortisol-reducing and glucocorticoidreceptor modulating interventions to prevent cognitive decline.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 17, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

Corticosteroids seem to be among the hormones with the most important effects on the brain function. Indeed, corticosteroids have been associated with effects on mood, stress, anxiety, sleep, appetite, as well as cognition.

Once released from the adrenal cortex, cortisol, the main glucocorticoid in humans, easily crosses the blood–brain barrier, owing to its lipophilic character. Cortisol binds to specific intracellular receptors in the brain, in particular in regions implicated in cognitive functions. Once activated, these receptors bind to “ hormone response elements” in the DNA and regulate the transcription of target genes.

The resulting effects on cognition seem to be complex and involve several cognitive domains. Different levels of cortisol likely produce different and even sometimes opposite effects. While some of these effects are acute, some appear to be long-lasting and may even involve long-term changes in the brain structure.

Altered Hypothalamic-Pituitary-Adrenal (HPA) axis functioning, and in particular high cortisol levels in the elderly have been associated with an increased risk for dementia and Alzheimer’s disease (AD).

A better understanding of these interrelationships between cortisol, cognition and dementia may open the door to new prevention and therapeutic options involving the HPA axis. The effects of cortisol on emotional memory had already led to therapeutic trials of corticosteroids and corticosteroid receptor antagonists/modulators in AD, as well as in treating or preventing post-traumatic stress disorder (PTSD), as well as in treating depression.

Glucocorticoid Receptors and Cortisol Effects on Cognition

Cortisol exerts its effects on cognition through two types of receptors: type I (Mineralocorticoid Receptors, MRs) and type II (Glucocorticoid Receptors, GRs). Surprisingly, the MRs display 6 to 10 times higher affinity for glucocorticoids, mainly cortisol, than GRs.

These receptors are expressed differently throughout the brain. Indeed, the hippocampus, mainly implicated in episodic memory, expresses both MRs and GRs, whilst the prefrontal cortex, primarily responsible for executive functions, only expresses GRs. While MRs have been associated with positive/enhancing effects on the cognitive performance, GRs have, on the contrary, been linked to negative inhibitory effects. In this regard, it has been found that infusion of a GR antagonist, but not of MR antagonist, in the medial prefrontal cortex of a mouse blocked the deleterious effects of glucocorticoids on working memory.

Cortisol effects on the hippocampus-related cognitive performance have often been described by the means of an inverted-U shape plot (Figure 1). Indeed, in the hippocampus, where both GRs and MRs are expressed, moderate levels of cortisol only activate the receptors with the higher affinity, i.e., MRs, leading to memory enhancement effects. As cortisol levels increase, this positive effect increases till MRs are saturated. Starting from this point, as cortisol levels rise, GRs are increasingly activated thus leading to increasingly detrimental effects on the memory. Distinctly, the effects of cortisol on executive functions are likely more linear. Since the prefrontal cortex region, mostly responsible for executive functions, only expresses GRs, higher levels of cortisol may lead to worsened executive functioning (Figure 2;; ). The fact that both adrenal insufficiency and Cushing’s disease have been associated with impaired declarative memory bolsters this biphasic effect hypothesis. Another argument is that the administration of the MR agonist fludrocortisone has been found to improve verbal and visuospatial memory performance in young as well as elderly healthy subjects; whereas the administration of hydrocortisone (mimicking the endogenous cortisol effects on both GRs and MRs) has been shown to enhance at lower doses yet impair at higher doses verbal memory retrieval in healthy subjects.

These effects that cortisol exerts on the brain structures involved in cognition are possibly mediated by modifications in responses to serotonin, in β-adrenergic receptor activation, in calcium influx, as well as in long-term potentiation (LTP), a process referring to a long-term strengthening of synaptic connections contributing to memory formation and consolidation. Indeed, GR activation facilitates β-adrenergic signaling thus leading to the formation of adenosine 3′,5′-cyclic monophosphate (cAMP) and cAMP-dependent protein kinase (PKA). This pathway, once activated, is thought to inhibit the medial prefrontal cortex thus leading to an impairment in frontal functions, in particular working memory. Glucocorticoids have also been found to display certain effects on the hippocampus via actions on the serotoninergic system following the same biphasic pattern as described in Figure 1. Indeed, glucocorticoids can promote via MRs and, at the same time, inhibit via GRs the 5HT1A activation in hippocampal CA1 pyramidal cells.

Moreover, glucocorticoids have been reported to alter LTP in opposite directions depending on the MR/GR activation ratio: when the MR/GR activation ratio is high (central part of the inverted U-shaped plot, Figure 1), LTP is enhanced thus improving long-term memory consolidation. On the contrary, when the MR/GR ratio is low (extremes of the inverted U-shaped plot, Figure 1), LTP is suppressed thus worsening long-term memory consolidation.

In clinical studies, most studies examining the link between cortisol levels and global cognitive performance among non-demented older adults found that higher cortisol levels have been associated with poorer overall cognitive performance. Likewise, most, even though not all studies exploring the relationship between episodic memory and cortisol levels have found an association between elevated cortisol and poorer episodic memory among older adults without dementia. These findings suggest that, even at levels that are within the normal range, cortisol can still activate GRs, and not just MRs. This also suggests that relatively small differences in cortisol levels can exhibit significant effects on memory performance. Studies exploring the relationship between cortisol levels and prefrontal cortex-mediated cognitive functions, mainly executive functions, processing speed and working memory, have found more discrepant results: while the expected negative association was reported in certain studies, other studies failed to find such an association.

The differences in populations, assessment tools, as well as the likely effects of possible confounding factors including age, gender, educational level, as well as other neuroendocrine and psychological factors might explain these discrepancies.

Cortisol and Cerebral Structural Changes

High cortisol has also been linked to decreased volume of several brain regions involved in cognitive functions. In fact, in a study by involving 4244 non-demented subjects, elevated evening cortisol was found to be associated with decreased volumes in all brain regions, in particular the gray matter. Similar findings have been reported in the dementia-free Framingham Heart Study participants: elevated cortisol was associated with decreased total brain volume, in particular decreased occipital and frontal gray matter volumes. In the same study, increased cortisol levels were associated with some microstructural changes, specifically in the corpus callosum and the posterior corona radiate.

In addition, high levels of cortisol have been linked to hippocampal atrophy. This atrophy can be the consequence of the exposure to increased cortisol levels. Indeed, in Cushing’s disease, the observed hippocampal atrophy is reversed following treatment and normalization of the cortisol levels. Yet, this atrophy can also be a cause of the elevated cortisol levels. Indeed, the hippocampus exerts an inhibitory effect on the HPA axis activity, and hence hippocampal atrophy might disinhibit the HPA axis leading to increased cortisol (; Figure 3).

These effects on the hippocampal volume may be partly due to changes in brain-derived neurotrophic factor (BDNF) expression in the hippocampus. Similarly to their effects on cognitive performance, MR activation seems to increase whereas GR activation seems to decrease BDNF expression in the hippocampus.

In a study by elevated salivary cortisol levels at the start and at the end of a cognitive task appointment have been associated with a poorer white matter structure, i.e., greater white matter hyperintensity volume and/or elevated general factor of tract mean diffusivity. These findings suggest that aside from the “acute effects” of cortisol on cognition, chronically elevated cortisol levels likely bring about brain structural changes that may reflect long-term cognitive deficits.

HPA-Axis Dysregulation, Cortisol and Alzheimer’s Disease Pathology, Disease Risk and Clinical Course

Glucocorticoids have been reported to promote oxidative stress and to increase amyloid β (Aβ) peptide toxicity in cultured hippocampal neurons. Besides, in a mouse model of AD, elevated cortisol has been linked to exacerbated Aβ peptide and tau pathology in the brain.

In primates, year-long high-dose exposure to glucocorticoids was associated with decreased insulin-degrading enzyme levels, a candidate protease for the clearance of Aβ in the brain. At the same time, the Aβ1-42/Aβ1-40 ratio was increased indicating a relative shift toward increased production of the more brain toxic Aβ1-42.

In a cross-sectional study examining the links between cardiovascular risk factors and Aβ brain burden as determined by Pittsburgh Compound B-positron emission tomography (PiB-PET), an association has been found between plasma cortisol and Aβ brain burden.

Together, these findings suggest that increased cortisol may induce and/or exacerbate cerebral AD pathology by increasing Aβ brain burden, tau pathology as well as oxidative stress, which can all contribute to neurodegeneration. Effects on Aβ likely entail decreasing Aβ clearance as well as promoting the cleavage of Aβ into the most toxic compound (Aβ1-42).

The aforementioned cerebral changes associated with elevated cortisol likely translate into findings of associations between increased cortisol levels and clinical features of AD, as shown in several clinical studies that reported increased cortisol levels in patients with clinical AD dementia, and cortisol levels have even been found to correlate with the severity of the cognitive impairment.

A prospective study by S found that elevated cortisol (as measured by the urinary free cortisol/creatinine ratio) and elevated intra-subject cortisol variability (as measured by the within-person urinary free cortisol/creatinine ratio variability) were associated with a 1.31- and 1.38-times increase in AD risk. Furthermore, in cognitively healthy older adults with Aβ positive PET imaging, high cortisol levels have been found to be associated with a faster decline in global cognition, in episodic memory, as well as in executive functioning, independently of age, sex, APOE genotype, or anxiety symptoms. In a population based cohort study in 537 non-demented older adults (65 years or more at baseline), we found salivary cortisol day profiles to be not associated with faster cognitive decline over an average 5.3 years. However, preliminary analysis suggests that higher morning salivary cortisol measures may be associated with slight decline in global cognition.

Higher plasma cortisol levels in patients with AD dementia have been associated with a more rapid cognitive decline in some studies. Similarly, found that high plasma cortisol levels were associated with faster cognitive decline in individuals with very mild or mild AD dementia.

In a cohort study from the Alzheimer Disease Neuroimaging Initiative (ADNI) investigating biomarkers able to predict progression from mild cognitive impairment (MCI) to AD within 1–6 years, plasma cortisol was one of the six biomarkers found to provide an accurate prediction.

Moreover, cortisol concentrations in the cerebrospinal fluid (CSF) have been found to be higher in subjects with dementia and MCI due to AD compared to control subjects. In MCI due to AD, high CSF cortisol was also predictive of a more rapid cognitive decline. Hence, elevated cortisol appears to contribute to exacerbate AD brain pathology, thereby contributing to the disease progression both pathologically and clinically. Cortisol levels appear to be increased at early stages of AD, and fasting plasma and CSF cortisol levels may even be pre-clinical markers.

These findings may be explained by increased Aβ neurotoxicity related to higher cortisol levels as well as neurodegeneration and functional impairment of the hippocampus occurring early in the course of the disease as both a consequence of exposure to high cortisol levels and a cause of HPA axis disinhibition, hence a vicious circle.

Cortisol, Cognition and Mediating Factors

Certain factors may further explain the links between cortisol, cognitive impairment and dementia. Indeed, some of these factors may bring about HPA axis alterations that could affect cognition and the risk for dementia, in particular AD. These factors may include life events, personality, sleep disorders, depression.

At the same time, some other factors such as metabolic syndrome, insulin resistance and effects on inflammation may mediate the effects of cortisol on cognition and brain structural changes.

Cortisol, Cognition, Trauma and Life Events

Early trauma (of physical, sexual or emotional nature) has been linked to long-term cognitive deficits in adulthood (consisting in impaired spatial working memory and pattern recognition memory) in a study by; however, this finding was not replicated in other studies. Early stress has also been shown to be associated with structural and functional changes in brain regions involved in cognitive functions, including the frontal cortex as well as the hippocampus.

Early trauma is also one of the most important established risk factors for PTSD. PTSD has been shown to be associated with an increased risk of dementia in both genders over an average of 8 years of follow-up (hazard ratio: 1.73[1.47, 2.02]). Nevertheless, found that the long-term cognitive deficits associated with PTSD were likely independent of earlier childhood adversity.

Aside from early trauma and PTSD, stressful life events have often been associated with HPA activation. Yet, some studies, conversely, showed decreased cortisol following stressful life events. Results of the studies exploring the relationship between life events and cognition have been discrepant. On the one hand, several studies highlighted associations between stressful events and poorer subsequent cognitive performance, in particular in memory and executive functions above and beyond the impact of depression. Importantly, stressful events have been also associated with an elevated risk of late-life dementia and late-life cerebral atrophy, and white matter lesions. On the other hand, other studies failed to find any association between stressful life events and cognitive performance in the elderly and some even showed a possible improvement in cognition following certain stressful events.

In a study exploring the mediation hypothesis between cortisol, life events and cognition in 796 non-demented subjects aged at least 65 we found elevated salivary cortisol levels to be linked to poorer cognitive performance, but this association was not related to life events.

These discrepancies regarding the relationships between life events and cortisol on the one hand, and life events and cognition on the other hand, may be explained by different life events displaying different effects on cortisol and thus on cognition.

Cortisol, Cognition and Personality

High neuroticism is the personality trait most consistently often associated with high cortisol. However, other studies found no association, or even an opposite link.

Higher neuroticism has also been reported to be cross-sectionally linked to lower cognitive performance above and beyond the effects of depression, especially to poorer episodic memory. In addition, high neuroticism scores have been found in association with elevated risk of AD.

A few studies examined the relationship between the other personality traits and cognitive performance and risk of dementia. Lower pre-morbid conscientiousness, agreeableness, openness and extraversion have been associated, although not consistently, with lower cognitive performance and higher risk for AD. In a cohort of memory clinic patients and cognitively healthy elderly volunteers we found lower extraversion and openness to correlate with CSF markers of AD pathology: tau, ptau-181, tau/Aβ1–42, and ptau-181/Aβ1–42 ratios, but not with the Aβ1–42 level.

In a population-based cohort study examining the interrelationships between cortisol, cognition and personality traits, salivary cortisol did not seem to mediate the link between personality traits and cognitive deficits.

Besides methodological differences, these observed discrepancies may be due to the impact of depression and/or anxiety which has been controlled for in a few studies but not in others, but also to the difficulties (in cross-sectional studies, mainly) to disentangle pre-morbid personality traits from the personality modifications accompanying the cognitive decline.

Cortisol, Cognition and Sleep Disorders

Cognitive impairment has been associated with more time spent in stage N1 (first step of non-rapid eye movement sleep) and less in stage N3 (third step of non-rapid eye movement sleep) and in REM sleep, lower sleep efficiency, and more wake after sleep onset, as well as more severe sleep disordered breathing (as evidenced by higher apnea/hypopnea index or AHI, and higher oxygen desaturation index or ODI).

In a study of the same research group, involving 456 elderly non-demented subjects, obstructive sleep apnea (OSA) has been found to be linked to cognitive impairment, but the relationship did not appear to be mediated by diurnal cortisol levels.

In other studies, OSA has been associated with increased nocturnal plasma cortisol levels. found that higher night-time cortisol was associated with worse cognitive performance, mainly affecting memory, above and beyond the apnea severity in a sample of patients with OSA.

Taken together, the results of these studies highlight links between cognitive performance and sleep disorders on the one hand, and between cortisol levels and cognitive functioning on the other hand, but do not provide evidence to support that cortisol may actually mediate the relationship between sleep disorders and cognitive impairment.

Cortisol, Cognition and Depression

Depression has been associated, on the one hand with HPA axis hyperactivity and impaired negative feedback, and on the other hand with cognitive deficits involving attention, episodic memory and executive functions. Depression has also been tied to late-life dementia, in particular with vascular and AD dementia. This association is not just a mere comorbidity, as late-life depression may also be a risk factor for both AD and vascular dementia. In the AGES-Reykjavik population-based study, both current major depressive disorder and high evening cortisol levels were associated with an higher risk of incident AD and non-AD dementia, but cortisol did not seem to be a major factor explaining the relation between depression and risk of dementia.

Some of the observed cognitive deficits in verbal and visual memory and executive functions may remain present even after the depressive symptoms fully remitted. Likewise, the HPA axis abnormalities associated with depression may persist even after remission, possibly constituting trait rather than state markers for depression, even though this remains a matter of debate.

Remission status in depression did not moderate the association between cognitive performance and the Dexamethasone suppression test ratio or the cortisol awakening response (CAR), defined by the increase in cortisol secretion after awakening. However, remission appeared to moderate the association between cortisol slope defined by the difference between maximal and minimal cortisol levels during the nyctemera, and certain cognitive tasks assessing processing speed and executive function. HPA axis alteration in depression may inhibit neurogenesis, partly through reducing BDNF which is involved in hippocampal neurogenesis, thus possibly explaining one of the mechanisms by which depression may be a risk factor for AD.

Delirium is common in AD, and it is associated with more rapid clinical disease progression. Depression symptoms and cognitive impairment have been independently associated with higher risk of developing delirium. In a yet-to be-published study by the same team, increased cortisol levels have been observed in patients with delirium suggesting HPA axis dysregulation to be involved in the pathophysiology of delirium. In a cohort of elderly patients undergoing elective cardiac surgery, pre-operative geriatric depression scale scores were found to predict post-operative delirium. However, pre-operative morning plasma cortisol levels were not associated with post-operative delirium in this study.

Whether and how HPA axis dysregulation and increased cortisol levels may contribute to the magnitude of cognitive and non-cognitive symptoms in AD, needs further investigation. In a study in patients with AD dementia, plasma cortisol levels have been shown to reflect the degree of cognitive deficits in AD dementia rather than the severity of the comorbid depression.

Altogether, these data suggest that, mostly, cognitive deficits linked to increased cortisol and HPA axis dysregulation cannot be entirely explained by a co-occurring depressive disorder. AD pathology may exacerbate HPA axis dysregulation which may contribute to the manifestation of depressive symptoms and to the severity of cognitive impairment and increase the risk of other non-cognitive syndromes, including delirium. Even though depression-associated HPA axis dysregulation may predispose to and/or exacerbate the course of AD, studies suggest a link between HPA axis dysregulation and AD itself above and beyond depression.

Cortisol, Cognition and the Metabolic Syndrome

Elevated cortisol levels have been tied to insulin resistance and metabolic syndrome, which in turn, have been associated with both AD and vascular dementia.. Hence, elevated cortisol may lead, through its metabolic syndrome-associated effects on glucose, blood pressure and lipids, to an increased cardiovascular risk. Indeed, higher cortisol has been associated with a higher number of carotid plaques. The resulting vascular lesions in the brain may directly induce cognitive disturbances, but can also contribute to the neurodegeneration observed in AD. Moreover, insulin resistance itself may negatively influence the amyloid cascade.

At the same time, AD-associated hypercortisolemia, present at very early stages, may also induce pre-diabetes. The resulting increased insulin secretion can further exacerbate the hypercortisolemia, thus possibly negatively affecting the course of AD.

Cortisol, Cognition and Inflammation

While cortisol is generally known to exert broad anti-inflammatory effects, high cortisol levels may activate NACHT, LRR and PYD domains-containing protein 1 (NLRP-1) inflammasome in hippocampal neurons, thus promoting neuroinflammation and thereby neuronal injury.

Moreover, certain cytokines, in particular IL-1-Beta and IL-6, which are also known to be involved in the pathophysiology of AD, can activate the HPA axis. The resulting increased cortisol can reinforce the toxic effects on the hippocampus exerted by the pro-inflammatory cytokines, thus contributing to the pathophysiology of AD.

Cortisol and Potential Preventive and Therapeutic Interventions for Alzheimer’s Disease:

Since increased cortisol has been associated with both AD pathology and more rapid clinical disease progression, and since most detrimental effects of cortisol are likely exerted via GRs, therapeutic interventions targeting the GRs have been investigated. Indeed, the GR antagonist mifepristone has been shown to decrease both Aβ and tau load in the brain as well as to improve the pathologically induced cognitive impairments in a triple-transgenic (3xTg AD) mouse model of AD. In a similar way, mifepristone has been shown to reduce the hippocampal Aβ levels and rescue the cognitive deficits induced by early life stress in APP/PS1 transgenic mice. As these pathological processes start years or even decades before the onset of the first symptoms, cortisol lowering or cortisol effects modulating interventions in midlife may slow down the development of amyloid pathology and neurodegeneration, and prevent cognitive decline in later life. Such interventions could prove useful, in particular in subjects at risk for developing clinical AD and prone to stress, and HPA-axis dysregulation. Prevention trials with focus on cortisol or HPA-axis in human subjects with normal cognition have not been reported so far, however.

One randomized controlled trial in a small sample of patients with mild to moderate AD dementia showed improvement of cognitive performance in memory tasks, but the premature termination did not allow any firm conclusions regarding efficacy. Other trials using mifepristone that were initiated were terminated without being published, indicating that these trials were not completed, or yielded negative results.

Also, several non-pharmacological intervention in subjects with MCI or dementia have shown cortisol lowering effects.

However, there has been some loss of interest in GR antagonists because of their side effects due to GRs being ubiquitous, especially as more selective molecules, namely GR modulators have been developed.

Glucocorticoid Receptor modulators have been shown to normalize basal glucocorticoid plasma levels, decrease hippocampal Aβ peptide deposition, inhibit neuroinflammation, and apoptotic processes, and improve cognitive performance in a mouse model of AD.

Another potential mechanism by which cortisol effects can be reduced pharmacologically is the inhibition of cortisol synthesis, one of the key enzymes being the 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). Currently, a phase II trial of an 11β-HSD1 inhibitor (UE2343) as a potential treatment for AD is being conducted.

Strengths and Limitations

This narrative review provides a concise overview of the different molecular, cellular, and clinical (including diagnostic, prognostic, and therapeutic) aspects of the interrelationships between cortisol, cognition, dementia, and AD. However, it does not cover all possible facets of these complex relationships. We focused on the most important and the most clinically relevant aspects of the topic, rather going in depth into one particular aspect of the topic.

Conclusion

There is a growing body of evidence that increased cortisol may be deleterious for the late-life cognitive performance, and may be associated with an increased risk for cognitive decline and dementia, in particular dementia due to AD. In patients with AD, the increased cortisol at preclinical and early clinical stages is associated with a poorer prognosis and a more rapid cognitive decline. Increased cortisol may represent a pathophysiological mediator between stressful life events, personality, mood, and sleep, and may increase both the risk of AD and the extent of symptoms at clinical stages of the disease. Yet, the exact underlying mediating factors are not fully understood. Direct deleterious cortisol effects on the hippocampus and on the prefrontal cortex are likely, but also cortisol links with metabolic syndrome and neuroinflammation; and HPA axis disinhibition due to neurodegeneration are other possible mechanisms that may explain the association of cortisol with late-life cognitive impairment and AD.

Further studies are needed to confirm the value of cortisol levels as a possible preclinical marker associated with higher risk, and/or as a prognostic parameter in subjects with clinical AD. Future research may also bring in new HPA-based interventions for the prevention and/or management of symptoms, and of the clinical progression of AD.

Author Contributions

SO participated in literature review and in writing the first draft of the manuscript. JP participated in literature review and revised the article.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References 124

  1. 1.

    Adler L. Wedekind D. Pilz J. Weniger G. Huether G. (1997 ). Endocrine correlates of personality traits: a comparison between emotionally stable and emotionally labile healthy young men. Neuropsychobiology 35 205–210.

    Not in our library10.1159/000119346

  2. 2.

    Albanese E. Preisig M. Castelao E. Ouanes S. Popp J. (2018 ). Salivary cortisol and 5y change in cognitive function in community dwelling, cognitively healthy older adults: the Psycolaus cohort study. Alzheimers Dement. 14:972

    Not in our library10.1016/j.jalz.2018.06.1304

  3. 3.

    Anacker C. Zunszain P. A. Carvalho L. A. Pariante C. M. (2011 ). The glucocorticoid receptor: pivot of depression and of antidepressant treatment? Psychoneuroendocrinology 36 415–425.

    Not in our library10.1016/j.psyneuen.2010.03.007

  4. 4.
    The overlap between vascular disease and Alzheimer’s disease - lessons from pathology · 2014
    No notice
  5. 5.

    Baglietto-Vargas D. Medeiros R. Martinez-Coria H. LaFerla F. M. Green K. N. (2013 ). Mifepristone alters amyloid precursor protein processing to preclude amyloid beta and also reduces tau pathology. Biol. Psychiatry 74 357–366.

    Not in our library10.1016/j.biopsych.2012.12.003

  6. 6.

    Baker L. D. Frank L. L. Foster-Schubert K. Green P. S. Wilkinson C. W. McTiernan A. (2010 ). Effects of aerobic exercise on mild cognitive impairment: a controlled trial. Arch. Neurol. 67 71–79.

    Not in our library10.1001/archneurol.2009.307

  7. 7.

    Ballenger J. C. Post R. M. Jimerson D. C. Lake C. R. Murphy D. Zuckerman M. (1983 ). Biochemical correlates of personality traits in normals: an exploratory study. Pers. Individ. Differ. 4 615–625.

    Not in our library10.1016/0191-8869(83)90116-2

  8. 8.

    Barsegyan A. Mackenzie S. M. Kurose B. D. McGaugh J. L. Roozendaal B. (2010 ). Glucocorticoids in the prefrontal cortex enhance memory consolidation and impair working memory by a common neural mechanism. Proc. Natl. Acad. Sci. U.S.A. 107 16655–16660.

    Not in our library10.1073/pnas.1011975107

  9. 9.

    Beluche I. Carriere I. Ritchie K. Ancelin M. L. (2010 ). A prospective study of diurnal cortisol and cognitive function in community-dwelling elderly people. Psychol. Med. 40 1039–1049.

    Not in our library10.1017/s0033291709991103

  10. 10.

    Besedovsky H. O. del Rey A. (2000 ). The cytokine-HPA axis feed-back circuit. Z. Rheumatol. 59(Suppl. 2), II/26–30.

    Not in our library10.1007/s003930070014

  11. 11.

    Boyle L. L. Lyness J. M. Duberstein P. R. Karuza J. King D. A. Messing S. (2010 ). Trait neuroticism, depression, and cognitive function in older primary care patients. Am. J. Geriatr. Psychiatry 18 305–312.

    Not in our library10.1097/jgp.0b013e3181c2941b

  12. 12.

    Bridges P. K. Jones M. T. (1968 ). Relationship of personality and physique to plasma cortisol levels in response to anxiety. J. Neurol. Neurosurg. Psychiatry 31 57–60.

    Not in our library10.1136/jnnp.31.1.57

  13. 13.

    Brunnstrom H. Passant U. Englund E. Gustafson L. (2013 ). History of depression prior to Alzheimer’s disease and vascular dementia verified post-mortem. Arch. Gerontol. Geriatr. 56 80–84.

    Not in our library10.1016/j.archger.2012.10.008

  14. 14.

    Burri A. Maercker A. Krammer S. Simmen-Janevska K. (2013 ). Childhood trauma and PTSD symptoms increase the risk of cognitive impairment in a sample of former indentured child laborers in old age. PLoS One 8:e57826.

    Not in our library10.1371/journal.pone.0057826

  15. 15.

    Canet G. Chevallier N. Zussy C. Desrumaux C. Givalois L. (2018 ). Central role of glucocorticoid receptors in Alzheimer’s Disease and depression. Front. Neurosci. 12:739

    Not in our library10.3389/fnins.2018.00739

  16. 16.

    Chopra S. Rathore A. Younas H. Pham L. V. Gu C. Beselman A. (2017 ). Obstructive sleep apnea dynamically increases nocturnal plasma free fatty acids, glucose, and cortisol during sleep. J. Clin. Endocrinol. Metab. 102 3172–3181.

    Not in our library10.1210/jc.2017-00619

  17. 17.

    Comijs H. C. van den Kommer T. N. Minnaar R. W. Penninx B. W. Deeg D. J. (2011 ). Accumulated and differential effects of life events on cognitive decline in older persons: depending on depression, baseline cognition, or ApoE epsilon4 status? J. Gerontol. B Psychol. Sci. Soc. Sci. 66(Suppl. 1), i111–i120.

    Not in our library10.1093/geronb/gbr019

  18. 18.

    Copinschi G. Caufriez A. (2013 ). Sleep and hormonal changes in aging. Endocrinol. Metab. Clin. North Am. 42 371–389.

    Not in our library10.1016/j.ecl.2013.02.009

  19. 19.

    Cox S. R. MacPherson S. E. Ferguson K. J. Royle N. A. Maniega S. M. Hernandez Mdel C. (2015 ). Does white matter structure or hippocampal volume mediate associations between cortisol and cognitive ageing? Psychoneuroendocrinology 62 129–137.

    Not in our library10.1016/j.psyneuen.2015.08.005

  20. 20.

    Csernansky J. G. Dong H. Fagan A. M. Wang L. Xiong C. Holtzman D. M. (2006 ). Plasma cortisol and progression of dementia in subjects with Alzheimer-type dementia. Am. J. Psychiatry 163 2164–2169.

    Not in our library10.1176/ajp.2006.163.12.2164

  21. 21.

    Daskalakis N. P. Lehrner A. Yehuda R. (2013 ). Endocrine aspects of post-traumatic stress disorder and implications for diagnosis and treatment. Endocrinol. Metab. Clin. North Am. 42 503–513.

    Not in our library10.1016/j.ecl.2013.05.004

  22. 22.

    de Kloet E. R. Meijer O. C. de Nicola A. F. de Rijk R. H. Joels M. (2018 ). Importance of the brain corticosteroid receptor balance in metaplasticity, cognitive performance and neuro-inflammation. Front. Neuroendocrinol. 49:124–145.

    Not in our library10.1016/j.yfrne.2018.02.003

  23. 23.

    de Kloet E. R. Oitzl M. S. Joels M. (1999 ). Stress and cognition: are corticosteroids good or bad guys? Trends Neurosci. 22 422–426.

    Not in our library10.1016/s0166-2236(99)01438-1

  24. 24.

    Deeg D. J. Huizink A. C. Comijs H. C. Smid T. (2005 ). Disaster and associated changes in physical and mental health in older residents. Eur. J. Public Health 15 170–174.

    Not in our library10.1093/eurpub/cki126

  25. 25.

    Diniz B. S. Butters M. A. Albert S. M. Dew M. A. Reynolds C. F. III (2013 ). Late-life depression and risk of vascular dementia and Alzheimer’s disease: systematic review and meta-analysis of community-based cohort studies. Br. J. Psychiatry 202 329–335.

    Not in our library10.1192/bjp.bp.112.118307

  26. 26.

    Domes G. Rothfischer J. Reichwald U. Hautzinger M. (2005 ). Inverted-U function between salivary cortisol and retrieval of verbal memory after hydrocortisone treatment. Behav. Neurosci. 119 512–517.

    Not in our library10.1037/0735-7044.119.2.512

  27. 27.

    Dong H. Csernansky J. G. (2009 ). Effects of stress and stress hormones on amyloid-beta protein and plaque deposition. J. Alzheimers Dis. 18 459–469.

    Not in our library10.3233/jad-2009-1152

  28. 28.

    Echouffo-Tcheugui J. B. Conner S. C. Himali J. J. Maillard P. DeCarli C. S. Beiser A. S. (2018 ). Circulating cortisol and cognitive and structural brain measures: the Framingham heart study. Neurology 91 e1961–e1970.

    Not in our library10.1212/wnl.0000000000006549

  29. 29.

    Edwards K. M. Kamat R. Tomfohr L. M. Ancoli-Israel S. Dimsdale J. E. (2014 ). Obstructive sleep apnea and neurocognitive performance: the role of cortisol. Sleep Med. 15 27–32.

    Not in our library10.1016/j.sleep.2013.08.789

  30. 30.

    Ennis G. E. An Y. Resnick S. M. Ferrucci L. O’Brien R. J. Moffat S. D. (2017 ). Long-term cortisol measures predict Alzheimer disease risk. Neurology 88 371–378.

    Not in our library10.1212/wnl.0000000000003537

  31. 31.

    Ferguson E. (2008 ). Health anxiety moderates the daytime cortisol slope. J. Psychosom. Res. 64 487–494.

    Not in our library10.1016/j.jpsychores.2008.01.011

  32. 32.

    Flatt J. D. Gilsanz P. Quesenberry C. P. Jr. Albers K. B. Whitmer R. A. (2017 ). Post-traumatic stress disorder and risk of dementia among members of a health care delivery system. Alzheimers Dement. 14 28–34.

    Not in our library10.1016/j.jalz.2017.04.014

  33. 33.

    Forget H. Lacroix A. Bourdeau I. Cohen H. (2016 ). Long-term cognitive effects of glucocorticoid excess in Cushing’s syndrome. Psychoneuroendocrinology 65 26–33.

    Not in our library10.1016/j.psyneuen.2015.11.020

  34. 34.

    Fountoulakis K. N. Pavlidis I. Tsolaki M. (2011 ). Life events and dementia: what is the nature of their relationship? Psychiatry Res. 190 156–158.

    Not in our library10.1016/j.psychres.2011.05.011

  35. 35.

    Fries E. Dettenborn L. Kirschbaum C. (2009 ). The cortisol awakening response (CAR): facts and future directions. Int. J. Psychophysiol. 72 67–73.

    Not in our library10.1016/j.ijpsycho.2008.03.014

  36. 36.

    Garcia-Banda G. Chellew K. Fornes J. Perez G. Servera M. Evans P. (2014 ). Neuroticism and cortisol: pinning down an expected effect. Int. J. Psychophysiol. 91 132–138.

    Not in our library10.1016/j.ijpsycho.2013.12.005

  37. 37.

    Geerlings M. I. Sigurdsson S. Eiriksdottir G. Garcia M. E. Harris T. B. Gudnason V. (2015 ). Salivary cortisol, brain volumes, and cognition in community-dwelling elderly without dementia. Neurology 85 976–983.

    Not in our library10.1212/wnl.0000000000001931

  38. 38.

    Geerlings M. I. Sigurdsson S. Eiriksdottir G. Phillips C. Jonsson P. V. Gudnason V. (2017 ). Late-life depression, salivary cortisol, and incident dementia: the ages-REYKJAVIK study. Alzheimers Dement. 13:854

    Not in our library10.1016/j.jalz.2017.06.1207

  39. 39.

    Gerritsen L. Geerlings M. I. Bremmer M. A. Beekman A. T. Deeg D. J. Penninx B. W. (2009 ). Personality characteristics and hypothalamic-pituitary-adrenal axis regulation in older persons. Am. J. Geriatr. Psychiatry 17 1077–1084.

    Not in our library10.1097/jgp.0b013e3181bd1be6

  40. 40.

    Goodman Y. Bruce A. J. Cheng B. Mattson M. P. (1996 ). Estrogens attenuate and corticosterone exacerbates excitotoxicity, oxidative injury, and amyloid beta-peptide toxicity in hippocampal neurons. J. Neurochem. 66 1836–1844.

    Not in our library10.1046/j.1471-4159.1996.66051836.x

  41. 41.

    Green K. N. Billings L. M. Roozendaal B. McGaugh J. L. LaFerla F. M. (2006 ). Glucocorticoids increase amyloid-beta and tau pathology in a mouse model of Alzheimer’s disease. J. Neurosci. 26 9047–9056.

    Not in our library10.1523/jneurosci.2797-06.2006

  42. 42.

    Haba-Rubio J. Marti-Soler H. Tobback N. Andries D. Marques-Vidal P. Waeber G. (2017 ). Sleep characteristics and cognitive impairment in the general population: the HypnoLaus study. Neurology 88 463–469.

    Not in our library10.1212/wnl.0000000000003557

  43. 43.

    Haba-Rubio J. Ouanes S. Franc Y. Marques-Vidal P. Waeber G. Vollenweider P. (2018 ). Do diurnal cortisol levels mediate the association between sleep disturbances and cognitive impairment? Neurobiol. Aging 69 65–67.

    Not in our library10.1016/j.neurobiolaging.2018.05.001

  44. 44.

    Hamer M. O’Donnell K. Lahiri A. Steptoe A. (2010 ). Salivary cortisol responses to mental stress are associated with coronary artery calcification in healthy men and women. Eur. Heart J. 31 424–429.

    Not in our library10.1093/eurheartj/ehp386

  45. 45.

    Herbert J. Lucassen P. J. (2016 ). Depression as a risk factor for Alzheimer’s disease: genes, steroids, cytokines and neurogenesis - what do we need to know? Front. Neuroendocrinol. 41:153–171.

    Not in our library10.1016/j.yfrne.2015.12.001

  46. 46.

    Herrera-Guzman I. Gudayol-Ferre E. Herrera-Abarca J. E. Herrera-Guzman D. Montelongo-Pedraza P. Padros Blazquez F. (2010 ). Major depressive disorder in recovery and neuropsychological functioning: effects of selective serotonin reuptake inhibitor and dual inhibitor depression treatments on residual cognitive deficits in patients with major depressive disorder in recovery. J. Affect. Disord. 123 341–350.

    Not in our library10.1016/j.jad.2009.10.009

  47. 47.

    Hinkelmann K. Wingenfeld K. Kuehl L. K. Fleischer J. Heuser I. Wiedemann K. (2015 ). Stimulation of the mineralocorticoid receptor improves memory in young and elderly healthy individuals. Neurobiol. Aging 36 919–924.

    Not in our library10.1016/j.neurobiolaging.2014.09.008

  48. 48.

    Huang C. W. Lui C. C. Chang W. N. Lu C. H. Wang Y. L. Chang C. C. (2009 ). Elevated basal cortisol level predicts lower hippocampal volume and cognitive decline in Alzheimer’s disease. J. Clin. Neurosci. 16 1283–1286.

    Not in our library10.1016/j.jocn.2008.12.026

  49. 49.

    Joels M. (2006 ). Corticosteroid effects in the brain: U-shape it. Trends Pharmacol. Sci. 27 244–250.

    Not in our library10.1016/j.tips.2006.03.007

  50. 50.

    Johansson L. Guo X. Waern M. Ostling S. Gustafson D. Bengtsson C. (2010 ). Midlife psychological stress and risk of dementia: a 35-year longitudinal population study. Brain 133(Pt 8), 2217–2224.

    Not in our library10.1093/brain/awq116

  51. 51.

    Johansson L. Skoog I. Gustafson D. R. Olesen P. J. Waern M. Bengtsson C. (2012 ). Midlife psychological distress associated with late-life brain atrophy and white matter lesions: a 32-year population study of women. Psychosom. Med. 74 120–125.

    Not in our library10.1097/psy.0b013e318246eb10

  52. 52.

    Jorm A. F. Mackinnon A. J. Christensen H. Henderson S. Scott R. Korten A. (1993 ). Cognitive functioning and neuroticism in an elderly community sample. Pers. Individ. Differ. 15 721–723.

    Not in our library10.1016/0191-8869(93)90013-s

  53. 53.

    Kim B. Feldman E. L. (2015 ). Insulin resistance as a key link for the increased risk of cognitive impairment in the metabolic syndrome. Exp. Mol. Med. 47:e149.

    Not in our library10.1038/emm.2015.3

  54. 54.

    Kino T. Jaffe H. Amin N. D. Chakrabarti M. Zheng Y. L. Chrousos G. P. (2010 ). Cyclin-dependent kinase 5 modulates the transcriptional activity of the mineralocorticoid receptor and regulates expression of brain-derived neurotrophic factor. Mol. Endocrinol. 24 941–952.

    Not in our library10.1210/me.2009-0395

  55. 55.

    Klaming R. Veltman D. J. Comijs H. C. (2016 ). The impact of personality on memory function in older adults-results from the longitudinal aging study Amsterdam. Int. J. Geriatr. Psychiatry 32 798–804.

    Not in our library10.1002/gps.4527

  56. 56.

    Kling M. A. Coleman V. H. Schulkin J. (2009 ). Glucocorticoid inhibition in the treatment of depression: can we think outside the endocrine hypothalamus? Depress Anxiety 26 641–649.

    Not in our library10.1002/da.20546

  57. 57.

    Kulstad J. J. McMillan P. J. Leverenz J. B. Cook D. G. Green P. S. Peskind E. R. (2005 ). Effects of chronic glucocorticoid administration on insulin-degrading enzyme and amyloid-beta peptide in the aged macaque. J. Neuropathol. Exp. Neurol. 64 139–146.

    Not in our library10.1093/jnen/64.2.139

  58. 58.

    Lante F. Chafai M. Raymond E. F. Pereira A. R. Mouska X. Kootar S. (2015 ). Subchronic glucocorticoid receptor inhibition rescues early episodic memory and synaptic plasticity deficits in a mouse model of Alzheimer’s disease. Neuropsychopharmacology 40 1772–1781.

    Not in our library10.1038/npp.2015.25

  59. 59.

    Lattanzi S. Silvestrini M. (2017 ). Letter re: long-term cortisol measures predict Alzheimer disease risk. Neurology 89:106.

    Not in our library10.1212/wnl.0000000000004074

  60. 60.

    LeBlanc J. Ducharme M. B. (2005 ). Influence of personality traits on plasma levels of cortisol and cholesterol. Physiol. Behav. 84 677–680.

    Not in our library10.1016/j.physbeh.2005.02.020

  61. 61.

    Lee B. K. Glass T. A. Wand G. S. McAtee M. J. Bandeen-Roche K. Bolla K. I. (2008 ). Apolipoprotein e genotype, cortisol, and cognitive function in community-dwelling older adults. Am. J. Psychiatry 165 1456–1464.

    Not in our library10.1176/appi.ajp.2008.07091532

  62. 62.

    Lee C. M. Huxley R. R. Wildman R. P. Woodward M. (2008 ). Indices of abdominal obesity are better discriminators of cardiovascular risk factors than BMI: a meta-analysis. J. Clin. Epidemiol. 61 646–653.

    Not in our library10.1016/j.jclinepi.2007.08.012

  63. 63.

    Lehallier B. Essioux L. Gayan J. Alexandridis R. Nikolcheva T. Wyss-Coray T. (2016 ). Combined plasma and cerebrospinal fluid signature for the prediction of midterm progression from mild cognitive impairment to Alzheimer disease. JAMA Neurol. 73 203–212.

    Not in our library10.1001/jamaneurol.2015.3135

  64. 64.

    Lesuis S. L. Weggen S. Baches S. Lucassen P. J. Krugers H. J. (2018 ). Targeting glucocorticoid receptors prevents the effects of early life stress on amyloid pathology and cognitive performance in APP/PS1 mice. Transl. Psychiatry 8:53.

    Not in our library10.1038/s41398-018-0101-2

  65. 65.

    Lok A. Mocking R. J. Ruhe H. G. Visser I. Koeter M. W. Assies J. (2012 ). Longitudinal hypothalamic-pituitary-adrenal axis trait and state effects in recurrent depression. Psychoneuroendocrinology 37 892–902.

    Not in our library10.1016/j.psyneuen.2011.10.005

  66. 66.

    Lupien S. J. Maheu F. Tu M. Fiocco A. Schramek T. E. (2007 ). The effects of stress and stress hormones on human cognition: implications for the field of brain and cognition. Brain Cogn. 65 209–237.

    Not in our library10.1016/j.bandc.2007.02.007

  67. 67.

    Lupien S. J. McEwen B. S. (1997 ). The acute effects of corticosteroids on cognition: integration of animal and human model studies. Brain Res. Brain Res. Rev. 24 1–27.

    Not in our library10.1016/s0165-0173(97)00004-0

  68. 68.

    Lupien S. J. McEwen B. S. Gunnar M. R. Heim C. (2009 ). Effects of stress throughout the lifespan on the brain, behaviour and cognition. Nat. Rev. Neurosci. 10 434–445.

    Not in our library10.1038/nrn2639

  69. 69.

    Lupien S. J. Nair N. P. Briere S. Maheu F. Tu M. T. Lemay M. (1999 ). Increased cortisol levels and impaired cognition in human aging: implication for depression and dementia in later life. Rev. Neurosci. 10 117–139.

    Not in our library10.1515/revneuro.1999.10.2.117

  70. 70.

    Lupien S. J. Wilkinson C. W. Briere S. Ng Ying Kin N. M. Meaney M. J. (2002 ). Acute modulation of aged human memory by pharmacological manipulation of glucocorticoids. J. Clin. Endocrinol. Metab. 87 3798–3807.

    Not in our library10.1210/jcem.87.8.8760

  71. 71.
    Association of childhood trauma with cognitive function in healthy adults: a pilot study · 2010
    No notice
  72. 72.

    Martocchia A. Stefanelli M. Falaschi G. M. Toussan L. Ferri C. Falaschi P. (2016 ). Recent advances in the role of cortisol and metabolic syndrome in age-related degenerative diseases. Aging Clin. Exp. Res. 28 17–23.

    Not in our library10.1007/s40520-015-0353-0

  73. 73.

    McEwen B. S. (2007 ). Physiology and neurobiology of stress and adaptation: central role of the brain. Physiol. Rev. 87 873–904.

    Not in our library10.1152/physrev.00041.2006

  74. 74.

    McGaugh J. L. Roozendaal B. (2002 ). Role of adrenal stress hormones in forming lasting memories in the brain. Curr. Opin. Neurobiol. 12 205–210.

    Not in our library10.1016/s0959-4388(02)00306-9

  75. 75.

    Meier B. Perrig-Chiello P. Perrig W. (2002 ). Personality and memory in old age. Aging Neuropsychol. Cogn. 9 135–144.

    Not in our library10.1076/anec.9.2.135.9544

  76. 76.

    Meir Drexler S. Wolf O. T. (2016 ). The role of glucocorticoids in emotional memory reconsolidation. Neurobiol. Learn. Mem. 142(Pt A), 126–134.

    Not in our library10.1016/j.nlm.2016.11.008

  77. 77.

    Miller G. E. Chen E. Zhou E. S. (2007 ). If it goes up, must it come down? Chronic stress and the hypothalamic-pituitary-adrenocortical axis in humans. Psychol. Bull. 133 25–45.

    Not in our library10.1037/0033-2909.133.1.25

  78. 78.

    Miller G. E. Cohen S. Rabin B. S. Skoner D. P. Doyle W. J. (1999 ). Personality and tonic cardiovascular, neuroendocrine, and immune parameters. Brain Behav. Immun. 13 109–123.

    Not in our library10.1006/brbi.1998.0545

  79. 79.

    Miller K. G. Wright A. G. Peterson L. M. Kamarck T. W. Anderson B. A. Kirschbaum C. (2016 ). Trait positive and negative emotionality differentially associate with diurnal cortisol activity. Psychoneuroendocrinology 68 177–185.

    Not in our library10.1016/j.psyneuen.2016.03.004

  80. 80.

    Nater U. M. Hoppmann C. Klumb P. L. (2010 ). Neuroticism and conscientiousness are associated with cortisol diurnal profiles in adults–role of positive and negative affect. Psychoneuroendocrinology 35 1573–1577.

    Not in our library10.1016/j.psyneuen.2010.02.017

  81. 81.

    Notarianni E. (2017 ). Cortisol: mediator of association between Alzheimer’s disease and diabetes mellitus? Psychoneuroendocrinology 81 129–137.

    Not in our library10.1016/j.psyneuen.2017.04.008

  82. 82.

    O’Banion M. K. (2013 ). It may take more than a shot: alternatives to immunotherapy for Alzheimer’s disease. Biol. Psychiatry 74 316–317.

    Not in our library10.1016/j.biopsych.2013.07.003

  83. 83.

    Ouanes S. Castelao E. Gebreab S. von Gunten A. Preisig M. Popp J. (2017a ). Life events, salivary cortisol, and cognitive performance in nondemented subjects: a population-based study. Neurobiol. Aging 51 1–8.

    Not in our library10.1016/j.neurobiolaging.2016.11.014

  84. 84.

    Ouanes S. Castelao E. von Gunten A. Vidal P. M. Preisig M. Popp J. (2017b ). Personality, cortisol, and cognition in non-demented elderly subjects: results from a population-based study. Front. Aging Neurosci. 9:63.

    Not in our library10.3389/fnagi.2017.00063

  85. 85.

    Pedersen W. A. Wan R. Mattson M. P. (2001 ). Impact of aging on stress-responsive neuroendocrine systems. Mech. Ageing Dev. 122 963–983.

    Not in our library10.1016/s0047-6374(01)00250-0

  86. 86.

    Pietrzak R. H. Laws S. M. Lim Y. Y. Bender S. J. Porter T. Doecke J. (2017 ). Plasma cortisol, brain amyloid-beta, and cognitive decline in preclinical Alzheimer’s disease: a 6-year prospective cohort study. Biol. Psychiatry Cogn. Neurosci. Neuroimaging 2 45–52.

    Not in our library10.1016/j.bpsc.2016.08.006

  87. 87.

    Pineau F. Canet G. Desrumaux C. Hunt H. Chevallier N. Ollivier M. (2016 ). New selective glucocorticoid receptor modulators reverse amyloid-beta peptide-induced hippocampus toxicity. Neurobiol. Aging 45 109–122.

    Not in our library10.1016/j.neurobiolaging.2016.05.018

  88. 88.

    Pomara N. Doraiswamy P. M. Tun H. Ferris S. (2002 ). Mifepristone (RU 486) for Alzheimer’s disease. Neurology 58 1436–1436.

    Not in our library10.1212/wnl.58.9.1436

  89. 89.

    Popp J. (2013 ). Delirium and cognitive decline: more than a coincidence. Curr. Opin. Neurol. 26 634–639.

    Not in our library10.1097/wco.0000000000000030

  90. 90.

    Popp J. Schaper K. Kolsch H. Cvetanovska G. Rommel F. Klingmuller D. (2009 ). CSF cortisol in Alzheimer’s disease and mild cognitive impairment. Neurobiol. Aging 30 498–500.

    Not in our library10.1016/j.neurobiolaging.2007.07.007

  91. 91.

    Popp J. Wolfsgruber S. Heuser I. Peters O. Hull M. Schroder J. (2015 ). Cerebrospinal fluid cortisol and clinical disease progression in MCI and dementia of Alzheimer’s type. Neurobiol. Aging 36 601–607.

    Not in our library10.1016/j.neurobiolaging.2014.10.031

  92. 92.

    Portella M. J. Harmer C. J. Flint J. Cowen P. Goodwin G. M. (2005 ). Enhanced early morning salivary cortisol in neuroticism. Am. J. Psychiatry 162 807–809.

    Not in our library10.1176/appi.ajp.162.4.807

  93. 93.

    Rock P. L. Roiser J. P. Riedel W. J. Blackwell A. D. (2014 ). Cognitive impairment in depression: a systematic review and meta-analysis. Psychol. Med. 44 2029–2040.

    Not in our library10.1017/s0033291713002535

  94. 94.

    Rothman S. M. Mattson M. P. (2010 ). Adverse stress, hippocampal networks, and Alzheimer’s disease. Neuromol. Med. 12 56–70.

    Not in our library10.1007/s12017-009-8107-9

  95. 95.

    Saigh P. A. Yasik A. E. Oberfield R. A. Halamandaris P. V. Bremner J. D. (2006 ). The intellectual performance of traumatized children and adolescents with or without posttraumatic stress disorder. J. Abnorm. Psychol. 115 332–340.

    Not in our library10.1037/0021-843x.115.2.332

  96. 96.

    Salvat-Pujol N. Labad J. Urretavizcaya M. de Arriba-Arnau A. Segalas C. Real E. (2017 ). Hypothalamic-pituitary-adrenal axis activity and cognition in major depression: the role of remission status. Psychoneuroendocrinology 76 38–48.

    Not in our library10.1016/j.psyneuen.2016.11.007

  97. 97.

    Sang Y. M. Wang L. J. Mao H. X. Lou X. Y. Zhu Y. J. (2018 ). The association of short-term memory and cognitive impairment with ghrelin, leptin, and cortisol levels in non-diabetic and diabetic elderly individuals. Acta Diabetol. 55 531–539.

    Not in our library10.1007/s00592-018-1111-5

  98. 98.

    Schaub C. Von Gunten A. Morin D. Wild P. Gomez P. Popp J. (2018 ). The effects of hand massage on stress and agitation among people with dementia in a hospital setting: a pilot study. Appl. Psychophysiol. Biofeedback [Epub ahead of print].

    Not in our library10.1007/s10484-018-9416-2

  99. 99.

    Schommer N. C. Kudielka B. M. Hellhammer D. H. Kirschbaum C. (1999 ). No evidence for a close relationship between personality traits and circadian cortisol rhythm or a single cortisol stress response. Psychol. Rep. 84(3 Pt 1), 840–842.

    Not in our library10.2466/pr0.1999.84.3.840

  100. 100.

    Segerstrom S. C. Geiger P. J. Boggero I. A. Schmitt F. A. Sephton S. E. (2016 ). Endogenous cortisol exposure and declarative verbal memory: a longitudinal study of healthy older adults. Psychosom. Med. 78 182–191.

    Not in our library10.1097/psy.0000000000000249

  101. 101.

    Starkman M. N. Giordani B. Gebarski S. S. Berent S. Schork M. A. Schteingart D. E. (1999 ). Decrease in cortisol reverses human hippocampal atrophy following treatment of Cushing’s disease. Biol. Psychiatry 46 1595–1602.

    Not in our library10.1016/s0006-3223(99)00203-6

  102. 102.

    Stefanelli M. Martocchia A. De Marinis E. A. Falaschi G. M. Romano G. Rufo M. (2014 ). Treatment of insulin resistance in the neurodegeneration. Recent Pat. CNS Drug Discov. 9 54–63.

    Not in our library10.2174/1574889809666140410093006

  103. 103.

    Sudheimer K. D. O’Hara R. Spiegel D. Powers B. Kraemer H. C. Neri E. (2014 ). Cortisol, cytokines, and hippocampal volume interactions in the elderly. Front. Aging Neurosci. 6:153.

    Not in our library10.3389/fnagi.2014.00153

  104. 104.

    Sundstrom A. Ronnlund M. Adolfsson R. Nilsson L. G. (2014 ). Stressful life events are not associated with the development of dementia. Int. Psychogeriatr. 26 147–154.

    Not in our library10.1017/s1041610213001804

  105. 105.

    Suri D. Vaidya V. A. (2013 ). Glucocorticoid regulation of brain-derived neurotrophic factor: relevance to hippocampal structural and functional plasticity. Neuroscience 239 196–213.

    Not in our library10.1016/j.neuroscience.2012.08.065

  106. 106.

    Tatomir A. Micu C. Crivii C. (2014 ). The impact of stress and glucocorticoids on memory. Clujul Med. 87 3–6.

    Not in our library10.15386/cjm.2014.8872.871.at1cm2

  107. 107.

    Tautvydaite D. Kukreja D. Antonietti J. P. Henry H. von Gunten A. Popp J. (2017 ). Interaction between personality traits and cerebrospinal fluid biomarkers of Alzheimer’s disease pathology modulates cognitive performance. Alzheimers Res. Ther. 9:6.

    Not in our library10.1186/s13195-017-0235-0

  108. 108.

    Terracciano A. Stephan Y. Luchetti M. Albanese E. Sutin A. R. (2017 ). Personality traits and risk of cognitive impairment and dementia. J. Psychiatr. Res. 89 22–27.

    Not in our library10.1016/j.jpsychires.2017.01.011

  109. 109.

    Terracciano A. Sutin A. R. An Y. O’Brien R. J. Ferrucci L. Zonderman A. B. (2014 ). Personality and risk of Alzheimer’s disease: new data and meta-analysis. Alzheimers Dement. 10 179–186.

    Not in our library10.1016/j.jalz.2013.03.002

  110. 110.

    Tiemensma J. Andela C. D. Biermasz N. R. Romijn J. A. Pereira A. M. (2016 ). Mild cognitive deficits in patients with primary adrenal insufficiency. Psychoneuroendocrinology 63 170–177.

    Not in our library10.1016/j.psyneuen.2015.09.029

  111. 111.

    Toledo J. B. Toledo E. Weiner M. W. Jack C. R. Jr. Jagust W. Lee V. M. (2012 ). Cardiovascular risk factors, cortisol, and amyloid-beta deposition in Alzheimer’s disease neuroimaging initiative. Alzheimers Dement. 8 483–489.

    Not in our library10.1016/j.jalz.2011.08.008

  112. 112.

    van Eck M. Berkhof H. Nicolson N. Sulon J. (1996 ). The effects of perceived stress, traits, mood states, and stressful daily events on salivary cortisol. Psychosom. Med. 58 447–458.

    Not in our library10.1097/00006842-199609000-00007

  113. 113.

    van Gelder B. M. Tijhuis M. Kalmijn S. Giampaoli S. Nissinen A. Kromhout D. (2006 ). Marital status and living situation during a 5-year period are associated with a subsequent 10-year cognitive decline in older men: the FINE study. J. Gerontol. B Psychol. Sci. Soc. Sci. 61 213–219.

    Not in our library10.1093/geronb/61.4.p213

  114. 114.

    Vogel S. Fernandez G. Joels M. Schwabe L. (2016 ). Cognitive adaptation under stress: a case for the mineralocorticoid receptor. Trends Cogn. Sci. 20 192–203.

    Not in our library10.1016/j.tics.2015.12.003

  115. 115.

    VonDras D. D. Powless M. R. Olson A. K. Wheeler D. Snudden A. L. (2005 ). Differential effects of everyday stress on the episodic memory test performances of young, mid-life, and older adults. Aging Ment. Health 9 60–70.

    Not in our library10.1080/13607860412331323782

  116. 116.

    Ward L. Mathias J. L. Hitchings S. E. (2007 ). Relationships between bereavement and cognitive functioning in older adults. Gerontology 53 362–372.

    Not in our library10.1159/000104787

  117. 117.

    Webster S. P. McBride A. Binnie M. Sooy K. Seckl J. R. Andrew R. (2017 ). Selection and early clinical evaluation of the brain-penetrant 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitor UE2343 (Xanamem). Br. J. Pharmacol. 174 396–408.

    Not in our library10.1111/bph.13699

  118. 118.

    Wolkowitz O. M. Burke H. Epel E. S. Reus V. I. (2009 ). Glucocorticoids. Mood, memory, and mechanisms. Ann. N. Y. Acad. Sci. 1179 19–40.

    Not in our library10.1111/j.1749-6632.2009.04980.x

  119. 119.

    Wolkowitz O. M. Reus V. I. (1999 ). Treatment of depression with antiglucocorticoid drugs. Psychosom. Med. 61 698–711.

    Not in our library10.1097/00006842-199909000-00011

  120. 120.

    Woods D. L. Beck C. Sinha K. (2009 ). The effect of therapeutic touch on behavioral symptoms and cortisol in persons with dementia. Forsch. Komplementmed. 16 181–189.

    Not in our library10.1159/000220479

  121. 121.

    Xavier F. M. Ferraz M. P. Trentini C. M. Freitas N. K. Moriguchi E. H. (2002 ). Bereavement-related cognitive impairment in an oldest-old community-dwelling Brazilian sample. J. Clin. Exp. Neuropsychol. 24 294–301.

    Not in our library10.1076/jcen.24.3.294.983

  122. 122.

    Yoshino A. Kimura Y. Yoshida T. Takahashi Y. Nomura S. (2005 ). Relationships between temperament dimensions in personality and unconscious emotional responses. Biol. Psychiatry 57 1–6.

    Not in our library10.1016/j.biopsych.2004.09.027

  123. 123.

    Zhang B. Zhang Y. Xu T. Yin Y. Huang R. Wang Y. (2017 ). Chronic dexamethasone treatment results in hippocampal neurons injury due to activate NLRP1 inflammasome in vitro. Int. Immunopharmacol. 49 222–230.

    Not in our library10.1016/j.intimp.2017.05.039

  124. 124.

    Zverova M. Fisar Z. Jirak R. Kitzlerova E. Hroudova J. Raboch J. (2013 ). Plasma cortisol in Alzheimer’s disease with or without depressive symptoms. Med. Sci. Monit. 19 681–689.

    Not in our library10.12659/msm.889110

Cited by papers we hold 4

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.